Sponsored

Jason Freeman, MD, MBA, and Shankar Sadasivan, PhD, discuss the poster “Immunoglobulins in Primary Progressive and Relapsing-Remitting Multiple Sclerosis” presented at ACTRIMS 2023. Sponsored By Novartis.

Jason Freeman, MD, MBA, and Brandon Brown, PharmD, discuss the poster “Five-Year Safety of Ofatumumab in People Living with Relapsing Multiple Sclerosis” presented at AAN 2023. Sponsored By Novartis.

Jason Freeman, MD, MBA, and D'Andra Parker, PhD, discuss highlights from ACTRIMS 2023, with a focus on diversity in clinical studies. Sponsored By Novartis.

Jason Freeman, MD, MBA, and Arsalan Syed, PhD, discuss highlights from the session “Multiple Sclerosis Disease Modifying Treatments” presented at AAN 2023. Sponsored By Novartis

Sponsored by Cerevel Therapeutics

Exploring the benefits and limitations of telemedicine for SMA.

The results of a phase 4 study demonstrate the efficacy of APOKYN® (apomorphine hydrochloride injection) treatment.

This year, Teva is celebrating the 25th anniversary of the FDA approval of COPAXONE® (glatiramer acetate injection), but the story goes back much further. Hear what some of Teva's most prominent R&D leaders have to say about the history and origins of the treatment.